2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)

Schenk, Nora; Lombart, A.; Frassoladti, A.; Neven, Patrick; Jérusalem, Guy; Deleu, Ines; Mebis, Jeroen; Maerevoet, Marie; Miller, Joel C.; Dias, Rogério

doi:10.1016/s1359-6349(07)70770-x

Cited by 32 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these trials, six were excluded since data regarding the osteonecrosis of the jaw could not be retrieved. Finally, 15 trials were included in the meta-analysis [7,8,10,17,[22][23][24][25][26][27][28][29][30][31][32].…”

Section: Resultsmentioning

confidence: 99%

Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis

Mauri

Valachis

Polyzos³

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

To estimate the cumulative randomized evidence for the overall incidence of bisphosphonates induced jaw osteonecrosis in adjuvant treatment of breast cancer. Systematic review and meta-analysis of randomized clinical trials. Trials were located through PubMed, ISI, Cochrane Library, and major cancer scientific meetings searches. We identified 15 studies reporting data on osteonecrosis of the jaw. A total of 10,694 randomized women were included, of whom 5,312 received bisphosphonates and 5,382 received either placebo or no treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis

Mauri

Valachis

Polyzos³

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…72 Zoledronic acid has demonstrated efficacy in preventing CTIBL and improving bone mineral density (BMD) above baseline in premenopausal and postmenopausal women with early BC who are receiving adjuvant endocrine therapy. [73][74][75][76][77][78][79] In addition to its bone-protective benefits, recent large, phase 3 studies demonstrated that ZOL can prolong DFS compared with standard therapy alone. 14,16,80 Completed Trials and Interim Reports The Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 12 (ABCSG-12) is a large, randomized, phase 3 trial that compared the efficacy of endocrine therapy with and without ZOL in 1803 premenopausal women with early stage BC.…”

Section: Clinical Evidence For Survival Benefits From Zoledronic Acidmentioning

confidence: 99%

Zoledronic acid use in cancer patients

Coleman

Cook

Hirsh

et al. 2010

Cancer

View full text Add to dashboard Cite

Bone is the most common site for metastasis from solid tumors, and the majority of patients will develop bone metastases during the natural course of their disease. Bisphosphonates are an effective treatment for preventing skeletal-related events in patients with bone metastases and may preserve functional independence and quality of life. Although several bisphosphonates have been investigated in patients with solid tumors, only zoledronic acid (ZOL) is approved by the US Food and Drug Administration and the European Medicines Agency for preventing skeletalrelated events in patients across a broad range of solid tumors. In addition, bisphosphonates, notably ZOL, prevent cancer treatment-induced bone loss in breast and prostate cancer patients who are receiving endocrine therapy. It also has been demonstrated that ZOL directly and indirectly inhibits cancer cell growth in vitro and growth and tumorigenesis in animal model systems. These properties may produce clinically meaningful benefits. In recent clinical studies in patients with cancer, ZOL improved overall and prolonged disease-free survival. Ongoing clinical trials in patients with solid tumors will provide further insight into the potential of ZOL to prevent distant metastases and improve survival. Cancer 2011;117:11-23. V C 2010 American Cancer Society.KEYWORDS: adjuvant setting, bisphosphonate, bone metastases, cancer, survival, zoledronic acid.During the progression of cancer, many patients will develop distant metastases, for which a common site is bone. 1For example, an estimated 75% of patients with advanced breast cancer (BC) or prostate cancer (PC), and 40% of patients with advanced lung cancer (LC) develop bone metastases.2,3 Without bone-targeted therapies, most patients with bone metastases will experience potentially debilitating skeletal-related events (SREs), such as pathologic fractures, spinal cord compression, the need for surgery or palliative radiotherapy to bone, or hypercalcemia of malignancy.1 These SREs can have debilitating consequences and reduce quality of life and survival. 4 Moreover, declines in performance status resulting from SREs could preclude the receipt of chemotherapy and radiotherapy by patients with some solid tumors. 5Bisphosphonates, which are inhibitors of osteoclast-mediated bone resorption, currently are the standard of care for preventing SREs in patients with bone metastases.6 Several bisphosphonates currently are approved by the US Food and Drug Administration and the European Medicines Agency for preventing SREs in patients with metastatic BC and multiple myeloma (MM). In addition, the nitrogen-containing bisphosphonate (N-BP) zoledronic acid (ZOL) has received widespread regulatory approval for patients with bone involvement from PC, LC, and the entire range of other solid tumors (OSTs). 6 In randomized phase 3 trials, ZOL (4 mg intravenously [iv] every 3 to 4 weeks [monthly]) demonstrated significant efficacy in delaying the onset and reducing the risk of SREs and in palliating bone pain, reducing analges...

show abstract

“…Bisphosphonates have an established role in treating postmenopausal osteoporosis and have demonstrated clinical benefits for preventing bone loss during therapy for BC (Coleman, 2008;Hadji, 2009). The largest body of evidence to date is for twice-yearly intravenous zoledronic acid (4 mg), which can prevent bone loss and improve BMD in premenopausal and postmenopausal women receiving adjuvant endocrine therapy for BC (total N ¼ 2598) (Schenk et al, 2007;Brufsky et al, 2008;Gnant et al, 2008). In Europe, current Arbeitsgemeinschaft Gynäkologische Onkologie e.V.…”

Section: Discussionmentioning

confidence: 99%

Assessment of fracture risk in women with breast cancer using current vs emerging guidelines

et al. 2010

View full text Add to dashboard Cite

BACKGROUND: Breast cancer (BC) therapies can have negative effects on bone. Current guidelines recommend antiresorptive therapy based on bone mineral density (BMD), and emerging guidelines include both clinical risk factors and BMD to assess the overall fracture risk. A retrospective, case -controlled study based on current and emerging guidelines was conducted in women with newly diagnosed BC to identify those who were at increased fracture risk based on current and emerging guidelines. METHODS: Baseline characteristics, fracture risk factors, and lumbar -spine (LS) and total-hip BMD in women with BC (88 premenopausal and 402 postmenopausal) were assessed to determine who would receive bisphosphonate therapy based on current and emerging guidelines. RESULTS: Among patients with estrogen-receptor-positive (ER þ ) BC, 18.8% of premenopausal and 36.9% of postmenopausal women were osteopenic at LS. In the postmenopausal cohort, osteoporosis was more prevalent in patients with ER þ vs ER -BC. Current guidelines identified 8.9% of patients as eligible for antiresorptive therapy, clinical risk factors alone identified 6.5%, and BMD plus clinical risk factors identified 28.6%. CONCLUSIONS: In addition to fracture risk factors present at BC diagnosis, cancer therapies leading to BMD loss further increase fracture risk. Evaluating both BMD and clinical risk factors may allow more effective identification of BC patients with elevated fracture risk.

show abstract

2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)

Cited by 32 publications

References 0 publications

Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis

Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis

Zoledronic acid use in cancer patients

Assessment of fracture risk in women with breast cancer using current vs emerging guidelines

Contact Info

Product

Resources

About